Jasmine Gowarty

Jasmine Gowarty practices at Texas Oncology PA in Mcallen, Texas.

Jasmine Gowarty's NPI, 1003263732, was assigned on May 23, 2016. Jasmine Gowarty graduated from Texas A&M College of Medicine - Bryan in 2016. Jasmine Gowarty holds Texas license S0891.

Jasmine Gowarty's primary practice is Texas Oncology PA, at 1901 S 2nd St, Mcallen, TX 78503 in Hidalgo County. The practice phone is (972) 997-8000.

Jasmine Gowarty's primary practice is Texas Oncology PA in Mcallen, Texas. Jasmine Gowarty is also affiliated with Rio Grande Regional Hospital. The medical group on file is Texas Oncology. Dmand AI also links Jasmine Gowarty to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Jasmine Gowarty practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Jasmine Gowarty's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Jasmine Gowarty is board certified in hematology by the American Board of Internal Medicine. Jasmine Gowarty is licensed in Texas.

CMS data shows 5,476 Medicare services from Jasmine Gowarty across 28 procedure codes in 2024, for 276 Medicare patients. Medicare paid $81,017 for them. Every service was in an office.

CMS counts 276 Medicare patients who saw Jasmine Gowarty in 2024. The largest group is 75 to 84, with 121 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 2.49, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Jasmine Gowarty's median patient age at 66, with 62% women.

In 2024, Jasmine Gowarty wrote 336 Medicare Part D claims for 93 patients. 90% of them were for generic drugs. CMS names the drug for 170 of them, across 9 drugs with 11 or more claims each, at $23,925 in total drug cost. In 2023, CMS named 15 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Jasmine Gowarty for performance year 2024, reported through an alternative payment model (APM). Jasmine Gowarty accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 6 papers to Jasmine Gowarty, published from 2018 to 2022. 2018 was the busiest year, with 5. Jasmine Gowarty has published most often in J Oncol Pharm Pract. Jasmine Gowarty's most frequent co-authors are Angela Lauren Birdwell, DO, Jordan Toulouse Buess, MD and Christian T. Cable, MD.

Dmand AI links Jasmine Gowarty to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Low Back Pain.

CMS Open Payments shows 104 general payments to Jasmine Gowarty from 33 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 75% of the total. Novartis Pharmaceuticals Corporation paid the most, $869.

Jasmine Gowarty graduated from Texas A&M College of Medicine - Bryan in 2016.

Jasmine Gowarty is in network with 19 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.